Stent News and Research RSS Feed - Stent News and Research

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.
Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM

Study assessing efficacy of Neovasc Reducer for treatment of Refractory Angina published in NEJM

Neovasc Inc. today announced that the final results from its COSIRA study assessing the efficacy and safety of the Neovasc Reducer for treatment of Refractory Angina, were published today in the New England Journal of Medicine. [More]
Scripps Green Hospital treats peripheral artery disease patient using new drug-coated balloon

Scripps Green Hospital treats peripheral artery disease patient using new drug-coated balloon

A doctor at Scripps Green Hospital this week became the first in California to use a new drug-coated balloon to treat peripheral artery disease in a patient since regulatory approval of the IN.PACT Admiral device in January by the Food and Drug Administration. [More]
Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Clinical trial results of drug-eluting stent for peripheral arterial disease presented at LINC 2015

Historic five-year results from the world’s largest clinical trial of a drug-eluting stent for treating peripheral arterial disease (PAD) were presented last week at the Leipzig Interventional Course, in Germany. The data confirm long-term patency for patients treated with Zilver® PTX®. [More]
Magnus Life Science commemorates unique partnership with UCL to advance bio-medical research

Magnus Life Science commemorates unique partnership with UCL to advance bio-medical research

Magnus Life Science is today celebrating its unique collaboration with University College London (UCL), one of the world's leading universities, to advance bio-medical research and bring real innovation to areas of high unmet medical need. [More]
EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

EMA recommends orphan designation to Magnus Growth's novel therapy for placental insufficiency

Magnus Life Science today announces that the European Medicines Agency's Committee for Orphan Medicinal Products has reached a positive decision on recommending orphan designation to Magnus Growth's novel therapy to treat placental insufficiency. [More]
Researchers examine ischemic complications in patients who receive flow-diverting stents

Researchers examine ischemic complications in patients who receive flow-diverting stents

The use of flow-diverting stents to treat intracranial aneurysms appears safe and highly successful. Recently, however, there have been reports of ischemic complications occurring in brain territories supplied by the parent artery in which the stent is placed and in brain regions fed by small arterial branches whose ostia are covered by the stent. [More]
Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Treatment for stroke: Intra-arterial treatment more effective than standard medical care for clot removal

Study results released today in The New England Journal of Medicine gave the world of stroke care more evidence that physicians are winning the battle against this debilitating disease, which affects as many as one in six people. [More]
Intra-arterial stroke treatment more effective than medical management with tPA, study finds

Intra-arterial stroke treatment more effective than medical management with tPA, study finds

Penumbra, Inc., the market leader in intra-arterial stroke treatment, announced that an independent study published online today in the New England Journal of Medicine found that intra-arterial stroke treatment, including the company's clot extraction technology, was shown to be significantly more effective than medical management with tissue plasminogen activator (tPA), which is the current standard of care. [More]
Real-time radiation-exposure feedback can help medical workers adopt safer radiation practices

Real-time radiation-exposure feedback can help medical workers adopt safer radiation practices

It's a sound that saves. A "real-time" radiation monitor that alerts by beeping in response to radiation exposure during cardiac-catheterization procedures significantly reduces the amount of exposure that medical workers receive, UT Southwestern Medical Center researchers found. [More]

Lombard Medical presents positive data from PYTHAGORAS PMA trial of Aorfix at VEITHsymposium

Lombard Medical, Inc., a medical device company focused on Endovascular Aneurysm Repair (EVAR) of abdominal aortic aneurysms (AAAs), today presented efficacy and safety data from the two-year follow up of the U.S. PYTHAGORAS pre-marketing approval (PMA) trial of Aorfix, the first and only endovascular stent graft with global approvals for the treatment of patients with aortic neck angulations up to 90 degrees. [More]
Surgical membrane delivers healing action of vitamin A

Surgical membrane delivers healing action of vitamin A

When blood vessels are damaged through surgery, it can trigger an endless cycle of scarring and repair. [More]
New study identifies crizotinib drug as possible new coating for drug-eluting stents

New study identifies crizotinib drug as possible new coating for drug-eluting stents

A new study has identified an FDA approved cancer drug, crizotinib, as a possible new coating for drug-eluting stents. Researchers found that crizotinib in mice helped prevent the narrowing of blood vessels after stenting without affecting the blood vessel lining. [More]
Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada to review evidence on the safety of long-term use of prescription blood-thinners

Health Canada is aware of and will be reviewing new evidence on the safety of long-term use of the prescription blood-thinners clopidogrel (Plavix) and prasugrel (Effient). [More]
Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

Boston Scientific starts PLATINUM Diversity trial to evaluate Promus PREMIER Stent System

As part of its commitment to innovation and improving patient outcomes, Boston Scientific Corporation has initiated the PLATINUM Diversity trial to evaluate the clinical performance of the Promus PREMIER Everolimus-Eluting Platinum Chromium Coronary Stent System in underserved patient populations, including women and people of color. [More]
Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson's sales increase 5.1% to $18.5 billion in Q3 2014

Johnson & Johnson today announced sales of $18.5 billion for the third quarter of 2014, an increase of 5.1% as compared to the third quarter of 2013. Operational results increased 5.8% and the negative impact of currency was 0.7%. Domestic sales increased 11.6%. International sales decreased 0.3%, reflecting operational growth of 1.0% and a negative currency impact of 1.3%. [More]
Multi-center study compares clinical performance of AAA procedures in virtual environment

Multi-center study compares clinical performance of AAA procedures in virtual environment

University Hospitals (UH) Case Medical Center and Simbionix recently launched a multi-center, randomized study comparing the clinical performance of abdominal aortic aneurysm (AAA) procedures with and without prior rehearsal in a virtual environment for physicians. [More]
Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announces initiation of ABSORB IV heart stent clinical trial

Abbott announced today the start of the ABSORB IV clinical trial, which will test whether its Absorb Bioresorbable Vascular Scaffold (BVS) is more cost-effective and offers a higher quality of life than a best-in-class, permanent, metallic drug eluting stent. [More]
Study shows 1 in 10 patients may not need surgery following heart attack

Study shows 1 in 10 patients may not need surgery following heart attack

Researchers from the Golden Jubilee National Hospital and the University of Glasgow have reported a study that shows one in ten patients may not need cardiac intervention following a heart attack and in those that do need stents, the procedure can be targeted more effectively. [More]
Ambulance administration of antiplatelet medication may help heart attack patients

Ambulance administration of antiplatelet medication may help heart attack patients

Ambulance administration of the antiplatelet medication ticagrelor to patients with a type of heart attack known as ST segment elevation myocardial infarction (STEMI) is not better than hospital administration, in terms of improving blood flow in blocked arteries before a revascularisation procedure, according to a new study presented at ESC Congress 2014 today. [More]
ESC Guidelines on diagnosis and treatment of aortic diseases published in European Heart Journal

ESC Guidelines on diagnosis and treatment of aortic diseases published in European Heart Journal

The first comprehensive ESC Guidelines on aortic diseases are published today. They are presented at ESC Congress 2014 by Task Force Chairpersons Professor Raimund Erbel (Germany) and Professor Victor Aboyans (France). [More]
Advertisement
Advertisement